Weekly Clinical Intelligence

The Hormonal Pulse

A weekly digest of endocrinology advances — new evidence, clinical practice shifts, drug approvals, and what they mean for your health. Written by Dr. Marie Noelle Kallas Chemaly. No filler. Every claim sourced. Designed for informed patients and fellow clinicians.

What We Cover

🔬

Thyroid

New evidence on Hashimoto's, nodule management, thyroid cancer surveillance, subclinical disease thresholds.

📊

Diabetes & CGM

Glucose management advances, CGM technology, insulin regimens, Type 1 and Type 2 practice shifts.

💊

GLP-1 & Obesity

Semaglutide, tirzepatide, survodutide — trial results, access issues, real-world outcomes, metabolic surgery updates.

🧬

PCOS & Reproductive

Diagnostic criteria debates, metabolic phenotyping, fertility implications, insulin resistance management.

🦴

Bone & Calcium

Osteoporosis treatment sequencing, vitamin D evidence, parathyroid disorders, fracture prevention.

⚕️

Clinical Practice

Guideline updates, society position statements, diagnostic tool advances, AI in endocrinology.

Latest Issues

The Hormonal Pulse publishes weekly. First issue coming soon — follow on LinkedIn or subscribe to be notified.

Coming Soon — Issue #1

The Hormonal Pulse Launches

Weekly endocrinology intelligence for patients and clinicians. Each issue covers the most significant clinical developments of the week — new trial results, guideline changes, drug approvals, and what they mean in practice. Every claim linked to its source.

Thyroid Diabetes GLP-1 PCOS

About This Digest

Evidence First

Every claim is linked to its source — peer-reviewed journals, society guidelines, regulatory filings. No unsourced assertions, no speculation presented as fact.

Clinician-Written

Written by Dr. Marie Noelle Kallas Chemaly — MD (USJ), PhD, DFMS Endocrinology (Paris Cité), member of the European Society of Endocrinology, founder of the Young Endocrinologists Network.

Relevant to MENA

Includes implications for patients in Lebanon and the Gulf — access, cost, availability of therapies, and how international evidence applies to our population.

Multilingual

Primary content in English with Arabic and French summaries. Designed to reach patients and physicians across Lebanon, the GCC, and the francophone world.